Evaluation of the efficacy of inhalation of essential oils in the complex therapy of community-acquired pneumonia theme
Translated by Google from Russian
ABSTRACT by WAC 14.00.05, PhD Dmitrieva Ekaterina
ABSTRACT titled "Evaluation of the effectiveness of inhalation of essential oils in the complex therapy of community-acquired pneumonia." disserCat - Scientific Electronic Library.
Share on vk Share on facebook Share on twitter Share on mymailru Share on odnoklassniki_ru Share on livejournal Share on surfingbird More Sharing Services
synopsis
thesis
Product code: 320046
year:
2006
Author of scientific work:
Dmitrieva, Ekaterina
PhD Degree:
PhD
Place thesis defense:
Moscow
Code Special WAC:
14.00.05
Speciality:
internal Medicine
Number of Pages:
102
Contents PhD dissertation Dmitrieva Ekaterina
Full Article Here
1. Introduction 4 p. A. The urgency of the problem. b. The purpose of this study. c. Objectives of the study. d. Scientific novelty. e. The practical significance of the work. f. Introduction. g. Issues for protection.
2. Chapter I. Review of the literature 9, p.
3. Chapter II Materials and methods 39 p. A. The stages of the study. b. Methods for studying the antimicrobial activity of vapors of essential oils in vitro against major pathogens of community-acquired pneumonia. c. Research Methods in Clinical evaluation of safety and efficacy of inhalation of essential oils in the complex treatment of community-acquired pneumonia.
Chapter 4. Research Results Sh 53 p. A. The results of experimental studies in vitro microbiological activity of essential oils in relation to the strains of major pathogens of community-acquired pneumonia b. The results for the clinical evaluation of safety and efficacy of inhalation of essential oils in the complex therapy with community-acquired pneumonia. Results of the study of inhalation of vapors immunotropic activity of essential oil of red thyme patients vnebol nichnoy pneumonia.
5. Chapter IV. Obsunadenie research results 80 p.
Introduction of the dissertation (part of the abstract) on "Estimating the efficiency of inhalation of essential oils in the treatment of community-acquired pneumonia complex"
The urgency of the problem.
Pneumonia remains one of the most widespread disease of industrial society (meets at 315 per 1,000 population, mortality from community-acquired pneumonia is 5% to 20% of nosocomial, older 30%). It should be noted that in recent years in our country, there is a steady upward trend in mortality from pneumonia and increased hospital mortality (Idrisov EM 2004). All this determines the relevance of research and development of new treatments.
Also a major problem is the low level of diagnosis of pneumonia (estimated A.G.Chuchalina about 60% of cases is not recognized), the lack of a uniform classification, the growth is particularly severe forms of pneumonia, an increased incidence of antibiotic resistance and the development of allergic reactions associated with the uncontrolled use of antimicrobials and their free vacation in the pharmacy network. (44). In these conditions requires the development and introduction of new methods that make it possible to reduce the duration of treatment and the need for preparations containing the chemical components that give side effects, allergic reactions and addictive to them. / Kokosov AN, 2005 /
It should be borne in mind that the treatment of community-acquired pneumonia is a problem not only medical but also social and economic as well as the costs of treating patients with this disease are increasing, making 6-8 thousand Euro in European countries, in the US reaching 15,000 euros each patient.
One of the major problems associated with the treatment of community-acquired pneumonia, is the development of microbial resistance to antimicrobials used / Sinopapnikov AI, 2005 /. This is largely dependent on the frequency of use of a particular class of antibacterial drugs in the practical work, and the data on antibiotic resistance vary not only by country but also in the cities (and even areas of the city). In this regard, given the high variability of the results, it is necessary studies to identify the causes of community-acquired pneumonia etiology and level of antibiotic resistance in all European countries (123). Most medical and social importance of the problem of the treatment of community-acquired pneumonia determines the considerable efforts that are spent on the search for new treatments for patients with this disease. Such methods include the use of inhalation and essential oils. It has been known beneficial effects of essential oils of many plants, such as eucalyptus, sage, lavender et al. On respiratory system (38). Also work with a demonstrably expressed immunotropic activity of essential oils in the treatment of diseases of broncho-pulmonary system (29). These treatment methods are widely used in folk medicine in many countries, however, lack the evidence base their performance, their lack of a clear and standardization of methods of individual applications do not allow wide use of this method of treatment in clinical practice. Based on the above, it can be assumed that the study of the mechanisms of action of essential oils, the use of standardized methods and their introduction into clinical practice for complex treatment of patients with infectious inflammatory diseases of the lower respiratory tract is an important task of modern pulmonology, which will increase the effectiveness of treatment in this group of patients .
All of the above and the purpose and objectives of our study.
The purpose of this study.
Evaluation of efficacy and safety of inhalation of essential oils in the complex therapy of community-acquired pneumonia.
Objectives of the study.
1. Experimental study of in vitro microbiological activity of essential oils in relation to the strains of major pathogens of community-acquired pneumonia.
2. Evaluate the safety of inhalation of essential oils in the complex treatment of community-acquired pneumonia.
3. To assess the clinical efficacy of inhalation of essential oils in the complex treatment of community-acquired pneumonia.
4. To study the effect of inhalation of essential oils on the state of humoral and cellular immunity in patients with community-acquired pneumonia.
5. To develop the optimal regimen and practical recommendations for the use of inhalation of essential oils in the complex treatment of community-acquired pneumonia.
Scientific novelty.
An experimental study in vitro microbiological activity of essential oils in relation to modern strains of major pathogens of community-acquired pneumonia (S .pneumoniae, K.pneumoniae, H.influezae, S.aureus). For the first time a comprehensive analysis of the action of inhalation of essential oils on the humoral and cellular immune status of patients revealed a correlation of changes of immunological and biochemical parameters of the dynamics of the clinical picture of the disease. A method for the treatment of pneumonia with the use of inhalation of essential oils in the complex therapy.
The practical significance of the work.
Our proposed method of inhalation treatment vapors of essential oils in the complex treatment of community-acquired pneumonia due to the antibacterial and immunotropic actions to accelerate the resolution of inflammation in the lungs, reducing the time of hospital stay in the absence of the period of observation of side effects from the therapy. Also, the proposed method can be used for the prevention of infectious inflammation in the lungs of patients in risk groups (patients with immunodeficiency, patients who have had SARS or influenza, prevention of nosocomial pneumonia in hospitalized patients).
The experimental and clinical data are expanding concepts of the mechanisms of action of essential oils on the human body.
Introduction.
Method of treatment of patients with community-acquired pneumonia with inhaled essential oils introduced into the practice of pulmonary department GKB№70 and Laboratories pulmonology department of clinical medicine Nims MSMSU. The research results are used in the pedagogical process at the Department of Immunology and the Laboratory MSMSU pulmonology department of clinical medicine Nims MSMSU.
Materials of work presented at the annual XIII National Congress on Respiratory Diseases in St. Petersburg, 2003, XIV National Congress on Respiratory Diseases in Moscow in 2004, at the XV National Congress on Respiratory Diseases in Moscow in 2005. According to the materials of the dissertation published 5 publications.
Issues for protection.
1. Antibacterial efficacy of vapors of essential oils in relation to the main pathogens of community-acquired pneumonia.
2. The positive influence of inhalation of essential oils in the complex therapy for community-acquired pneumonia.
3. Activity Immunotropic application inhalation of essential oils in the complex treatment of community-acquired pneumonia.
Conclusion dissertation on "Internal Medicine", Dmitrieva, Ekaterina
Conclusions.
1. In an in vitro study revealed that the highest antimicrobial activity against strains of major pathogens of community-acquired pneumonia (St. pneumoniae ZTZ, H. Influenzae № 964, H. Influenzae № 1095 H. Influenzae beskaps. № 9, H. Influenzae demon doghouse. № 11, K. Pneumoniae K-16, K. Pneumoniae K-2, K. Pneumoniae K-204, S. Auerus 1991) of essential oil of red thyme.
2. Essential oils of eucalyptus and basil in vitro are effective only against St. Pneumoniae ZTZ and lavender - S. Aureus 1991. Adding essential oils of basil and eucalyptus to red thyme reduces its antimicrobial activity.
3. Inhalation of essential oil of red thyme in complex therapy of community-acquired pneumonia is a safe method of treatment of patients with community-acquired pneumonia.
4. Inhalation of essential oil of red thyme in the complex therapy is an effective treatment of community-acquired pneumonia, contributing to a more rapid resolution of infiltrative changes in the lungs, reduce inflammation in the bronchial tree, reducing the length of stay in hospital.
5. Inhalation of essential oil of red thyme have immunotropic activity, manifested in the increase in the number of T-lymphocytes and the functional activity of phagocytes in patients with community-acquired pneumonia. and
Practical recommendations:
1. In light of the progress made in the data for patients with CAP recommended the use of inhaled vapors of essential oil of red thyme daily 5 minutes, 1 times a day, for 7 days in the complex treatment of this disease.
2. In the course of examination and treatment recommended conducting immunological examination, which must include phenotyping of peripheral blood lymphocytes, the definition of the functional activity of phagocytes, the content IgA, IgM, IgG and serum total IgE.
References dissertation research PhD Dmitrieva, Ekaterina, 2006
1. Abramov Zh, Ok- GI Man and antioxidant substances. - JL: Nauka, 1985. - 230 p.
2. Antibiotic therapy. Practical Guide / Ed. LS Stratchounski, YB Belousov, SN Kozlov. M., 2000.
3. Arinstein AI Radchenko NM, Peter KM, Serkova AA World of fragrant plants. - M .: Kolos, 1983. - 176 p.
4. Baraboi VA Biological effects of plant phenolic compounds. - Kiev: Naukova Dumka, 1976. - 260 p.
5. Baraboi VA Plant phenolics and human health. - M .: Nauka, 1984. -160 c.
6. Brehman II Man and biologically active substances. - 2nd ed., Revised. -M .: Nauka, 1981. - 120 p.
7. Brandtner P., D. Sluchenkov Aromatherapy. Carl Hadek, 1997 - 187 p.
8. X. Walji Aromatherapy. - Rostov-on-Don: Phoenix, 1997. - 315 p.
9. Vladimirov YA, Azizov OA, AI Deev Free radicals in living systems // Results in science and technology. Ser. Biofizika.-1991-T29.-S1-249.
10. Nosocomial infections / Ed. VP Wenzel. M., 1990.
11. Gary D. Yang Aromatherapy. - M .: Young Living, 1997. - 158 C.1. C j!>
12. Dmitriev MT, Zaharchenko MP, Stepanov EV, Visnapuu LY Effect of volatile production on air ionization // Hygiene and Medicine. - 1984, - № 8. - S. 82-83.
13. AE Eremenko, Nikolaev VV Kostin NF Volatile fraction of volatile production on the basis of essential oils as part of treatment and rehabilitation facilities for chronic bronchitis // Therapeutic Archives. 1987. - №3 - s.126-130.
14. Zyukov DG, A. EN Technology and equipment essential oil production. M .: Food Industry, 1979. - 191 p.
15. Treasurers VP Mikhailov L. Superweak radiation in intercellular vzaimodeystviyah.- Novosibirsk, 1981.
16. Kashkin KP, Cara 3.0. Immune reactivity and antibiotic therapy. -A .: Medicine, 1984. - 199 p.
17. Koloshin NA, Mazulin AV Fedyukovich NI Vivifying balms, elixirs and extracts. - 1997. - 239 p.
18. Lukomskii GI Shulutko ML Bronchology. M .: Medicine. 1973 359s.
19. Mayansky AN, DN Mayansky Essays on neutrophils and macrophages. - Novosibirsk: Nauka, 1989.- 344s.
20. Meerson FZ Overall adjustment mechanism and prevention. - M .: Medicine, 1973.- 356 p.
21. S. Mirgorodskaya Aromatherapy. - M .: NAVEUS, 1997. - 120 p.
22. Nikolaev AG On the biological role of the components of essential oils // IV International Congress on essential oils. - Tbilisi, 1968. - T. 2-AS 130-136.fOt
23. Nikolaev BB, AE Eremenko, Ivanov, IK Biological activity of essential oils. - M .: Medicine, 1987. - 144 p.
24. VV Nikolaev, VI Zinkovich Natural curative factors and immunological reactivity. - Moscow, 1996. - 176 p.
25. VV Nikolaev, VI Zinkovich Aromatic plant bioregulators. - Moscow, 1995. - 143 p.
26. VV Nikolaev, Zinkovich VI, Razykov AY Aromatherapy Health at work and at home. - Moscow, 1997. - 158 p.
27. VV Nikolaev Aromatherapy: a guide. M .: Medicine, 2000.
28. Nikolaev VV Eremenko AE Biological activity of essential oils. M .: Medicine, 1987. - 144 p.
29. VV Nikolaev, VI Zinkovich Aromas of plants and human health. - Moscow, 1997. - 206 p.
30. Orange IE Natural curative factors and biological rhythms. -M .: Medicine, 1988. - 285 p.
31. Ostapchuk IF, Akimov YA, Zaharchenko GS et al. aerophytotherapy - a method of rehabilitation and secondary prevention of lung diseases // volatile. Bacterial diseases. -Kiev: Nauk.dumka, 1985.- s.113-114.
32. Paleev NR Diseases of the respiratory system. M .: Medicine, 2000.- 728 p.
33. Ponomarenko GN Chervinskaya AV Konovalov, SI Inhalation terapiya.- SPb., DES, 1998.-234C
34. Pyatkin KD, Krivoshein YS Microbiology. M., 1980.
35. D. Redford Family aromatherapy. - M .: Terra, 1997. - 226 p.
36. 1. Soldatenko SS Kashchenko GF, Pidaev AV Aromatherapy. Prevention and treatment of essential oils. Second edition, revised and enlarged. Simferopol; Tauris, 2001.
37. Soldatchenko SS, Nikolaev VV Karalenka ES Gladun MI Essential oils of ancient medicine. - Simferopol: Tauris, 1995.-47 p.
38. Handbook of Clinical Microbiology / Ed. V.V.Tets. SPb., 1994.
39. Sorokina TS History of medicine. - M., 1994. - 381 p.
40. FS Tanasienko Essential Oils: The content and composition in plants.
41. Naukova Dumka, 1985. - 263 p.
42. Watt Mir amazing flavors. Email newsletter. The chemical composition of essential oils. Issue 4. http://www.yoursuccess.ru/aroma.
43. GN Uzhegov Recipes ancient medicine. - Smolensk: Rusich, 1997.455 p.
44. Chuchalin AG, Sinopalnikov AI, Stratchounski JI.C., Kozlov RS Community-acquired pneumonia in adults: guidelines for diagnosis, treatment and prevention. - M., LLC "Publishing House, M-West", 2006. 76 p.
45. Chuchalin AG White Paper. / Pulmonary. Moscow, 2003
46. Chuchalin AG, AN Tsoi Diagnosis and treatment of pneumonia from the standpoint of medicine evidence. Consilium-Medicum, 2002, Volume 04, N12
47. Yarilin AA Fundamentals of immunology: a textbook. Moscow. Medicine. 1999. S250-252.
48. Asquith S. The use of aromatherapy in wound care. J Wound Care. 1999 Jun; 8 (6): 318-20.
49. Avis A. Aromatherapy in practice. Nurs Stand. 1999 Mar 3-9; 13 (24): 14-5.
50. Baker J. Essential oils: a complementary therapy in wound management. J Wound Care. 1998 Jul; 7 (7): 355-7.
51. Black JM. Essential oils and miscarriage. Midwifery Today Int Midwife. 2000 Winter; (56): 5, 68.
52. Bartlett JG, Dowell SF, Mandell LA, et al. Guidelines from the Infectious Diseases Society of America: practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis. 2000; 31: 347-382.
53. Baumrucker SJ. Complementary medicine and the scientific method: mainstreaming proven "alternative" therapies. Am J Hosp Palliat Care. 2002 Nov-Dec; 19 (6): 369-71.
54. Bent S. Aromatherapy: ineffective treatment or effective placebo? Eff Clin Pract. 2000 Jul-Aug; 3 (4): 188-90.
55. Blanc PD, Trupin L, Earnest G, Katz PP, Yelin EH, Eisner MD. Alternative therapies among adults with a reported diagnosis of asthma or rhinosinusitis: data from a population-based survey. Chest. 20011. Nov; 120 (5): 1461-7.
56. Buchbauer G. On the biological properties of fragrance compounds and essential oils Wien Med Wochenschr. 2004 Nov; 154 (21-22): 539-47.60. .
57. Blasi F, Tarsia P, Aliberti S, Cosentini R, Allegra L. Chlamydia pneumoniae and Mycoplasma pneumoniae. Semin Respir Crit Care Med. 2005 Dec; 26 (6): 617-24.
58. Bukle J. Aromatherapy for health professionals. Holistic practices help with life transitions. Beginnings. 2005 Winter; 25 (l): 18
59. Buckle J. Clinical aromatherapy. Therapeutic uses for essential oils. Adv Nurse Pract. 2002 May; 10 (5): 67-8, 88. Review PMID: 12420533
60. Baker S. ATS policy on the conservation of plants used in aromatherapy. Coplement Ther Clin Pract. 2005 May; 11 (2): 137-8.
61. Blasi F. The pathogenesis of community-acquired pneumonia. Eur Respir Rev 2004; 13: 91,80-84
62. Belcher I. Aromatherapy growing rapidly. Beginnings. 1996 Feb; 16 (2): 4.
63. Buchbauer G, Jirovetz L, Jager W, Dietrich H, Plank C. Aromatherapy: evidence for sedative effects of the essential oil of lavender after inhalation. Z Naturforsch C. 1991 Nov-Dec; 46 (l 1-12): 1067-72
64. Braga PC, Dal Sasso M, Culici M, Galastri L, Marceca MT, GufFanti EE. Antioxidant potential of thymol determined by chemiluminescence inhibition in human neutrophils and cell-free systems. Pharmacology. 2006; 76 (2): 61-8.Epub 2005 Nov 11.
65. Hasani A, Pavia D, Toms N, Dilworth P, Agnew JE. Effect of aromatics on lung mucociliary clearance in patients with chronic airways obstruction. J Altern Complement Med. 2003 Apr;9(2):243-9.
66. Caramia G, Pastorelli G. Antipneumococca! vaccine: up date and prospective. Minerva Pediatr. 2005 Oct;57(5):229-41.
67. Casado JA, Merino J, Cid J, Subira ML, Sanchez-Ibarrola A Oxidizing agents and free radicals in biomedicine Rev Med Univ Navarra. 1996 Jul-Sep;40(3):31-40.
68. Grabenstein J. ImmunoFacts. Vaccines and Immunologic Drugs. Wolters Kluwer Health, Inc.; 2006
69. DeLeo FR. Modulation of phagocyte apoptosis by bacterial pathogens. Apoptosis. 2004 Jul;9(4):399-413.
70. Ewig S., Schlochtermeier M., Goke N., Niederman M.S. Applying Sputum as a Diagnostic Tool in Pneumonia // Chest. 2002. - Vol. 121. - P. 1486-1492.
71. Eschenbruch N. "A risk for life and health?" Alternative medicine practitioners, pharmacologists and drug regulation in the 1970's Schweiz Rundsch Med Prax. 2006 Apr 19;95(16):652-5.
72. Edwards-Jones V, Greenwood JE; Manchester Burns Research Group. What's new in burn microbiology? James Laing Memorial Prize Essay 2000. Bums. 2003 Feb;29(l): 15-24.и/
73. European Respiratory Society/European Lung Foundation. European Lung White Book. The First Comprehensive Survey on Respiratory Health in Europe. Loddenkemper R, Gibson GJ, Sibille Y, eds. Sheffield, UK, ERSJ, 2003
74. Edwards-Jones V, Greenwood JE; Manchester Burns Research Group. What's new in burn microbiology? James Laing Memorial Prize Essay 2000. Burns. 2003 Feb;29(l):15-24.
75. Ernst E, White A. The BBC survey of complementary medicine use in the UK. Complement Ther Med. 2000 Mar;8(l):32-6.
76. Forman HJ, Torres M Signaling by the respiratory burst in macrophages. IUBMB Life. 2001 Jun;51(6):365-71.
77. Freymann H, Rennie T, Bates I, Nebel S, Heinrich M. Knowledge and Use of Complementary and Alternative Medicine among British Undergraduate Pharmacy Students. Pharm World Sci. 2006 May 11
78. Foster WM. Mucociliary transport and cough in humans. Pulm Pharmacol Ther. 2002;15(3):277-82.
79. Faustova ME. The bactericidal action of some essential oils on the causative agents of acute and chronic inflammatory lung diseases Zh Mikrobiol Epidemiol Immunobiol. 1993 Nov-Dec;(6): 117-8.
80. File TM. Community-acquired pneumonia. Lancet. 2003 Dec 13;362(9400): 1991 -2001.
81. Gotfried M.H. Epidemiology of clinically diagnosed community-acquired pneumonia in the primary care setting: results from the 1999-2000 respiratory surveillance program // Am. J. Med. 2001. - Vol. 11 l(suppl 1). - P. 25-29.jlL
82. Galla JH. IgA nephropathy. Kidney Int 1995; 47: 377-387.
83. Hiemstra P.S. Immunoglobulin A in asthma: friend or foe? Eur Respir J 1998; 12:517-518
84. Hall K, Giles-Corti B. Complementary therapies and the general practitioner. A survey of Perth GPs. Aust Fam Physician. 2000 Jun;29(6):602-6.
85. Happel KI, Nelson S. Alcohol, immunosuppression, and the lung. Proc Am Thorac Soc. 2005;2(5):428-32.
86. Janeway C. Immunobiology: the immune system in health and disease.
87. Jones ML, Mulligan MS, Flory CM, Ward PA, Warren JS. Potential role of monocyte chemoattractant protein 1/JE in monocyte/macrophage-dependent IgA immune complex alveolitis in the rat. J Immunol 1992; 149: 2147-2154.
88. Kiffin R, Bandyopadhyay U, Cuervo AM. Oxidative stress and autophagy. Antioxid Redox Signal. 2006 Jan-Feb;8(l-2):152-62.
89. Kobayashi SD, Voyich JM, Burlak C, DeLeo FR. Neutrophils in the innate immune response. Arch Immunol Ther Exp (Warsz). 2005 Nov-Dec;53(6):505-17
90. Kim R, Emi M, Tanabe K, Murakami S, Uchida Y, Arihiro K. Regulation and interplay of apoptotic and non-apoptotic cell death. J Pathol. 2006 Feb;208(3):319-26.
91. Kupczyk M, Kuna P. Mucolytics in acute and chronic respiratory tract disorders. II.Uses for treatment and antioxidant properties Pol Merkuriusz Lek.2002 Mar;12(69):248-52.г/3
92. Lamm ME, Nedrud JG, Kaetzel CS, Mazanec MB. IgA and mucosal defense. APMIS 1995; 103: 241-246.
93. Morton HC, van Egmond M, van de Winkel JG. Structure and function of human IgA Fc receptors (Fc alpha R). Crit Rev Immunol 1996; 16: 423—440.
94. Mayaud C, Fartoukh M, Prigent H, Lavole A, Gounand V, Parrot A. Acute forms of diffuse interstitial hypoxemic pneumonia in immunocompetent' patients. Rev Pneumol Clin. 2005 Apr;61(2):70-7.
95. Mandell LA. Related Articles, Update on community-acquired pneumonia. New pathogens and new concepts in treatment. Postgrad Med. 2005 Oct;118(4):35-6, 41-6.
96. Moraes TJ, Zurawska JH, Downey GP. Neutrophil granule contents in thepathogenesis of lung injury. Curr Opin Hematol. 2006 Jan;13(l):21-7.t
97. MacMahon S, Kermode S. A clinical trial of the effect of aromatherapy Complement TherNurs Midwifery. 2004 Feb;10(l):58-60. Patol Fiziol Eksp Тег. 1990 Jan-Feb;( 1 ):27-30
98. Norton L. Complementary therapies in practice: the ethical issues. J Clin Nurs. 1995 Nov;4(6):343-8.
99. Neiss A., Elkharrat D., Kohno S., Hospitalisation costs for community-acquired pneumonia (CAP) in France (F), Germany (D), Japan (J) and USA. ERS congress 2004. Poster # 182.
100. Pettigrew AC, King MO, McGee K, Rudolph C. Complementary therapy use by women's health clinic clients. Altern Ther Health Med. 2004 Nov-Dec;10(6):50-5
101. Philipp B. Aroma therapy: there are hardly any limitations in this gentle method Pflege Z. 1999 Qct;52(10):696-9.ft
102. Pirotta MV, Cohen MM, Kotsirilos V, Farish SJ. Complementary therapies: have they become accepted in general practice? Med J Aust. 2000 Feb 7; 172(3): 105-9.
103. Roots R. Estimation of life times and diffusion distances of radicals involved in X-ray-induced DNA strand breaks or killing of mammalian cells // Radiat. Res.-1975.- Vol. 64.-P.306-320
104. Stocks N, Turnidge J, Crockett A. Lower respiratoiy tract infections and community acquired pneumonia in adults. Aust Fam Physician. 2004 May;33(5):297-301.
105. Sawazaki K, Sakuraba H, Masudai F, Ishii C, Yokoyama K. Use of complementaiy and alternative medicines among factory workers: investigation of workers in manufacturing Sangyo Eiseigaku Zasshi. 2005 Nov;47(6):254-8.
106. Segal AW. How neutrophils kill microbes. Annu Rev Immunol. 2005;23:197-223.
107. Schafer Т. Epidemiology of complementary alternative medicine for asthma and allergy in Europe and Germany. Ann Allergy Asthma Immunol. 2004 Aug;93(2 Suppl 1):S5-10.
108. Thomas RE, Jefferson TO, Demicheli V, Rivetti D. Influenza vaccination for health-care workers who work with elderly people in institutions: a systematic review. Lancet Infect Dis. 2006 May;6(5):273-9.
109. Wills PJ, Cole PJ. Mucolytic and mucokinetic therapy. Pulm Pharmacol. 1996 Aug;9(4): 197-204.
110. Wark PA, McDonald V, Jones AP. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev. 2005 Jul 20;(3)
111. Waite S, Jeudy J, White CS. Acute lung infections in normal and immunocompromised hosts. Radiol Clin North Am. 2006 Mar;44(2):295-3156th ed. New York, 2005, 823 p
112. Woodhead M. Community-acquired pneumonia in Europe: causative pathogens and resistance patterns Eur Respir J 2002; 20: Suppl. 36, 20s-27s
113. Zhao RJ, Koo BS, Kim GW, Jang EY, Lee JR, Kim MR, Kim SC, Kwon YK, Kim KJ, Huh TL, Kim DH, Shim I, Yang CH. The essential oil from Angelica gigas NAKAI suppresses nicotine sensitization.Biol Pharm Bull. 2005 Dec;28(12):2323-6.
Обратите внимание, представленные выше научные тексты размещены для ознакомления и получены посредством распознавания оригинальных текстов диссертаций (OCR). В связи с чем, в них могут содержаться ошибки, связанные с несовершенством алгоритмов распознавания.
В PDF файлах диссертаций и авторефератов, которые мы доставляем, подобных ошибок нет.
Научная библиотека диссертаций и авторефератов disserCat http://www.dissercat.com/content/otsenka-effektivnosti-primeneniya-ingalyatsii-efirnykh-masel-v-kompleksnoi-terapii-vnebolnic#ixzz3I2dm00cn
Want to see more scientific studies on essential oils?
www.essentialoilskeptic.com
Translated by Google from Russian
ABSTRACT by WAC 14.00.05, PhD Dmitrieva Ekaterina
ABSTRACT titled "Evaluation of the effectiveness of inhalation of essential oils in the complex therapy of community-acquired pneumonia." disserCat - Scientific Electronic Library.
Share on vk Share on facebook Share on twitter Share on mymailru Share on odnoklassniki_ru Share on livejournal Share on surfingbird More Sharing Services
synopsis
thesis
Product code: 320046
year:
2006
Author of scientific work:
Dmitrieva, Ekaterina
PhD Degree:
PhD
Place thesis defense:
Moscow
Code Special WAC:
14.00.05
Speciality:
internal Medicine
Number of Pages:
102
Contents PhD dissertation Dmitrieva Ekaterina
Full Article Here
1. Introduction 4 p. A. The urgency of the problem. b. The purpose of this study. c. Objectives of the study. d. Scientific novelty. e. The practical significance of the work. f. Introduction. g. Issues for protection.
2. Chapter I. Review of the literature 9, p.
3. Chapter II Materials and methods 39 p. A. The stages of the study. b. Methods for studying the antimicrobial activity of vapors of essential oils in vitro against major pathogens of community-acquired pneumonia. c. Research Methods in Clinical evaluation of safety and efficacy of inhalation of essential oils in the complex treatment of community-acquired pneumonia.
Chapter 4. Research Results Sh 53 p. A. The results of experimental studies in vitro microbiological activity of essential oils in relation to the strains of major pathogens of community-acquired pneumonia b. The results for the clinical evaluation of safety and efficacy of inhalation of essential oils in the complex therapy with community-acquired pneumonia. Results of the study of inhalation of vapors immunotropic activity of essential oil of red thyme patients vnebol nichnoy pneumonia.
5. Chapter IV. Obsunadenie research results 80 p.
Introduction of the dissertation (part of the abstract) on "Estimating the efficiency of inhalation of essential oils in the treatment of community-acquired pneumonia complex"
The urgency of the problem.
Pneumonia remains one of the most widespread disease of industrial society (meets at 315 per 1,000 population, mortality from community-acquired pneumonia is 5% to 20% of nosocomial, older 30%). It should be noted that in recent years in our country, there is a steady upward trend in mortality from pneumonia and increased hospital mortality (Idrisov EM 2004). All this determines the relevance of research and development of new treatments.
Also a major problem is the low level of diagnosis of pneumonia (estimated A.G.Chuchalina about 60% of cases is not recognized), the lack of a uniform classification, the growth is particularly severe forms of pneumonia, an increased incidence of antibiotic resistance and the development of allergic reactions associated with the uncontrolled use of antimicrobials and their free vacation in the pharmacy network. (44). In these conditions requires the development and introduction of new methods that make it possible to reduce the duration of treatment and the need for preparations containing the chemical components that give side effects, allergic reactions and addictive to them. / Kokosov AN, 2005 /
It should be borne in mind that the treatment of community-acquired pneumonia is a problem not only medical but also social and economic as well as the costs of treating patients with this disease are increasing, making 6-8 thousand Euro in European countries, in the US reaching 15,000 euros each patient.
One of the major problems associated with the treatment of community-acquired pneumonia, is the development of microbial resistance to antimicrobials used / Sinopapnikov AI, 2005 /. This is largely dependent on the frequency of use of a particular class of antibacterial drugs in the practical work, and the data on antibiotic resistance vary not only by country but also in the cities (and even areas of the city). In this regard, given the high variability of the results, it is necessary studies to identify the causes of community-acquired pneumonia etiology and level of antibiotic resistance in all European countries (123). Most medical and social importance of the problem of the treatment of community-acquired pneumonia determines the considerable efforts that are spent on the search for new treatments for patients with this disease. Such methods include the use of inhalation and essential oils. It has been known beneficial effects of essential oils of many plants, such as eucalyptus, sage, lavender et al. On respiratory system (38). Also work with a demonstrably expressed immunotropic activity of essential oils in the treatment of diseases of broncho-pulmonary system (29). These treatment methods are widely used in folk medicine in many countries, however, lack the evidence base their performance, their lack of a clear and standardization of methods of individual applications do not allow wide use of this method of treatment in clinical practice. Based on the above, it can be assumed that the study of the mechanisms of action of essential oils, the use of standardized methods and their introduction into clinical practice for complex treatment of patients with infectious inflammatory diseases of the lower respiratory tract is an important task of modern pulmonology, which will increase the effectiveness of treatment in this group of patients .
All of the above and the purpose and objectives of our study.
The purpose of this study.
Evaluation of efficacy and safety of inhalation of essential oils in the complex therapy of community-acquired pneumonia.
Objectives of the study.
1. Experimental study of in vitro microbiological activity of essential oils in relation to the strains of major pathogens of community-acquired pneumonia.
2. Evaluate the safety of inhalation of essential oils in the complex treatment of community-acquired pneumonia.
3. To assess the clinical efficacy of inhalation of essential oils in the complex treatment of community-acquired pneumonia.
4. To study the effect of inhalation of essential oils on the state of humoral and cellular immunity in patients with community-acquired pneumonia.
5. To develop the optimal regimen and practical recommendations for the use of inhalation of essential oils in the complex treatment of community-acquired pneumonia.
Scientific novelty.
An experimental study in vitro microbiological activity of essential oils in relation to modern strains of major pathogens of community-acquired pneumonia (S .pneumoniae, K.pneumoniae, H.influezae, S.aureus). For the first time a comprehensive analysis of the action of inhalation of essential oils on the humoral and cellular immune status of patients revealed a correlation of changes of immunological and biochemical parameters of the dynamics of the clinical picture of the disease. A method for the treatment of pneumonia with the use of inhalation of essential oils in the complex therapy.
The practical significance of the work.
Our proposed method of inhalation treatment vapors of essential oils in the complex treatment of community-acquired pneumonia due to the antibacterial and immunotropic actions to accelerate the resolution of inflammation in the lungs, reducing the time of hospital stay in the absence of the period of observation of side effects from the therapy. Also, the proposed method can be used for the prevention of infectious inflammation in the lungs of patients in risk groups (patients with immunodeficiency, patients who have had SARS or influenza, prevention of nosocomial pneumonia in hospitalized patients).
The experimental and clinical data are expanding concepts of the mechanisms of action of essential oils on the human body.
Introduction.
Method of treatment of patients with community-acquired pneumonia with inhaled essential oils introduced into the practice of pulmonary department GKB№70 and Laboratories pulmonology department of clinical medicine Nims MSMSU. The research results are used in the pedagogical process at the Department of Immunology and the Laboratory MSMSU pulmonology department of clinical medicine Nims MSMSU.
Materials of work presented at the annual XIII National Congress on Respiratory Diseases in St. Petersburg, 2003, XIV National Congress on Respiratory Diseases in Moscow in 2004, at the XV National Congress on Respiratory Diseases in Moscow in 2005. According to the materials of the dissertation published 5 publications.
Issues for protection.
1. Antibacterial efficacy of vapors of essential oils in relation to the main pathogens of community-acquired pneumonia.
2. The positive influence of inhalation of essential oils in the complex therapy for community-acquired pneumonia.
3. Activity Immunotropic application inhalation of essential oils in the complex treatment of community-acquired pneumonia.
Conclusion dissertation on "Internal Medicine", Dmitrieva, Ekaterina
Conclusions.
1. In an in vitro study revealed that the highest antimicrobial activity against strains of major pathogens of community-acquired pneumonia (St. pneumoniae ZTZ, H. Influenzae № 964, H. Influenzae № 1095 H. Influenzae beskaps. № 9, H. Influenzae demon doghouse. № 11, K. Pneumoniae K-16, K. Pneumoniae K-2, K. Pneumoniae K-204, S. Auerus 1991) of essential oil of red thyme.
2. Essential oils of eucalyptus and basil in vitro are effective only against St. Pneumoniae ZTZ and lavender - S. Aureus 1991. Adding essential oils of basil and eucalyptus to red thyme reduces its antimicrobial activity.
3. Inhalation of essential oil of red thyme in complex therapy of community-acquired pneumonia is a safe method of treatment of patients with community-acquired pneumonia.
4. Inhalation of essential oil of red thyme in the complex therapy is an effective treatment of community-acquired pneumonia, contributing to a more rapid resolution of infiltrative changes in the lungs, reduce inflammation in the bronchial tree, reducing the length of stay in hospital.
5. Inhalation of essential oil of red thyme have immunotropic activity, manifested in the increase in the number of T-lymphocytes and the functional activity of phagocytes in patients with community-acquired pneumonia. and
Practical recommendations:
1. In light of the progress made in the data for patients with CAP recommended the use of inhaled vapors of essential oil of red thyme daily 5 minutes, 1 times a day, for 7 days in the complex treatment of this disease.
2. In the course of examination and treatment recommended conducting immunological examination, which must include phenotyping of peripheral blood lymphocytes, the definition of the functional activity of phagocytes, the content IgA, IgM, IgG and serum total IgE.
References dissertation research PhD Dmitrieva, Ekaterina, 2006
1. Abramov Zh, Ok- GI Man and antioxidant substances. - JL: Nauka, 1985. - 230 p.
2. Antibiotic therapy. Practical Guide / Ed. LS Stratchounski, YB Belousov, SN Kozlov. M., 2000.
3. Arinstein AI Radchenko NM, Peter KM, Serkova AA World of fragrant plants. - M .: Kolos, 1983. - 176 p.
4. Baraboi VA Biological effects of plant phenolic compounds. - Kiev: Naukova Dumka, 1976. - 260 p.
5. Baraboi VA Plant phenolics and human health. - M .: Nauka, 1984. -160 c.
6. Brehman II Man and biologically active substances. - 2nd ed., Revised. -M .: Nauka, 1981. - 120 p.
7. Brandtner P., D. Sluchenkov Aromatherapy. Carl Hadek, 1997 - 187 p.
8. X. Walji Aromatherapy. - Rostov-on-Don: Phoenix, 1997. - 315 p.
9. Vladimirov YA, Azizov OA, AI Deev Free radicals in living systems // Results in science and technology. Ser. Biofizika.-1991-T29.-S1-249.
10. Nosocomial infections / Ed. VP Wenzel. M., 1990.
11. Gary D. Yang Aromatherapy. - M .: Young Living, 1997. - 158 C.1. C j!>
12. Dmitriev MT, Zaharchenko MP, Stepanov EV, Visnapuu LY Effect of volatile production on air ionization // Hygiene and Medicine. - 1984, - № 8. - S. 82-83.
13. AE Eremenko, Nikolaev VV Kostin NF Volatile fraction of volatile production on the basis of essential oils as part of treatment and rehabilitation facilities for chronic bronchitis // Therapeutic Archives. 1987. - №3 - s.126-130.
14. Zyukov DG, A. EN Technology and equipment essential oil production. M .: Food Industry, 1979. - 191 p.
15. Treasurers VP Mikhailov L. Superweak radiation in intercellular vzaimodeystviyah.- Novosibirsk, 1981.
16. Kashkin KP, Cara 3.0. Immune reactivity and antibiotic therapy. -A .: Medicine, 1984. - 199 p.
17. Koloshin NA, Mazulin AV Fedyukovich NI Vivifying balms, elixirs and extracts. - 1997. - 239 p.
18. Lukomskii GI Shulutko ML Bronchology. M .: Medicine. 1973 359s.
19. Mayansky AN, DN Mayansky Essays on neutrophils and macrophages. - Novosibirsk: Nauka, 1989.- 344s.
20. Meerson FZ Overall adjustment mechanism and prevention. - M .: Medicine, 1973.- 356 p.
21. S. Mirgorodskaya Aromatherapy. - M .: NAVEUS, 1997. - 120 p.
22. Nikolaev AG On the biological role of the components of essential oils // IV International Congress on essential oils. - Tbilisi, 1968. - T. 2-AS 130-136.fOt
23. Nikolaev BB, AE Eremenko, Ivanov, IK Biological activity of essential oils. - M .: Medicine, 1987. - 144 p.
24. VV Nikolaev, VI Zinkovich Natural curative factors and immunological reactivity. - Moscow, 1996. - 176 p.
25. VV Nikolaev, VI Zinkovich Aromatic plant bioregulators. - Moscow, 1995. - 143 p.
26. VV Nikolaev, Zinkovich VI, Razykov AY Aromatherapy Health at work and at home. - Moscow, 1997. - 158 p.
27. VV Nikolaev Aromatherapy: a guide. M .: Medicine, 2000.
28. Nikolaev VV Eremenko AE Biological activity of essential oils. M .: Medicine, 1987. - 144 p.
29. VV Nikolaev, VI Zinkovich Aromas of plants and human health. - Moscow, 1997. - 206 p.
30. Orange IE Natural curative factors and biological rhythms. -M .: Medicine, 1988. - 285 p.
31. Ostapchuk IF, Akimov YA, Zaharchenko GS et al. aerophytotherapy - a method of rehabilitation and secondary prevention of lung diseases // volatile. Bacterial diseases. -Kiev: Nauk.dumka, 1985.- s.113-114.
32. Paleev NR Diseases of the respiratory system. M .: Medicine, 2000.- 728 p.
33. Ponomarenko GN Chervinskaya AV Konovalov, SI Inhalation terapiya.- SPb., DES, 1998.-234C
34. Pyatkin KD, Krivoshein YS Microbiology. M., 1980.
35. D. Redford Family aromatherapy. - M .: Terra, 1997. - 226 p.
36. 1. Soldatenko SS Kashchenko GF, Pidaev AV Aromatherapy. Prevention and treatment of essential oils. Second edition, revised and enlarged. Simferopol; Tauris, 2001.
37. Soldatchenko SS, Nikolaev VV Karalenka ES Gladun MI Essential oils of ancient medicine. - Simferopol: Tauris, 1995.-47 p.
38. Handbook of Clinical Microbiology / Ed. V.V.Tets. SPb., 1994.
39. Sorokina TS History of medicine. - M., 1994. - 381 p.
40. FS Tanasienko Essential Oils: The content and composition in plants.
41. Naukova Dumka, 1985. - 263 p.
42. Watt Mir amazing flavors. Email newsletter. The chemical composition of essential oils. Issue 4. http://www.yoursuccess.ru/aroma.
43. GN Uzhegov Recipes ancient medicine. - Smolensk: Rusich, 1997.455 p.
44. Chuchalin AG, Sinopalnikov AI, Stratchounski JI.C., Kozlov RS Community-acquired pneumonia in adults: guidelines for diagnosis, treatment and prevention. - M., LLC "Publishing House, M-West", 2006. 76 p.
45. Chuchalin AG White Paper. / Pulmonary. Moscow, 2003
46. Chuchalin AG, AN Tsoi Diagnosis and treatment of pneumonia from the standpoint of medicine evidence. Consilium-Medicum, 2002, Volume 04, N12
47. Yarilin AA Fundamentals of immunology: a textbook. Moscow. Medicine. 1999. S250-252.
48. Asquith S. The use of aromatherapy in wound care. J Wound Care. 1999 Jun; 8 (6): 318-20.
49. Avis A. Aromatherapy in practice. Nurs Stand. 1999 Mar 3-9; 13 (24): 14-5.
50. Baker J. Essential oils: a complementary therapy in wound management. J Wound Care. 1998 Jul; 7 (7): 355-7.
51. Black JM. Essential oils and miscarriage. Midwifery Today Int Midwife. 2000 Winter; (56): 5, 68.
52. Bartlett JG, Dowell SF, Mandell LA, et al. Guidelines from the Infectious Diseases Society of America: practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis. 2000; 31: 347-382.
53. Baumrucker SJ. Complementary medicine and the scientific method: mainstreaming proven "alternative" therapies. Am J Hosp Palliat Care. 2002 Nov-Dec; 19 (6): 369-71.
54. Bent S. Aromatherapy: ineffective treatment or effective placebo? Eff Clin Pract. 2000 Jul-Aug; 3 (4): 188-90.
55. Blanc PD, Trupin L, Earnest G, Katz PP, Yelin EH, Eisner MD. Alternative therapies among adults with a reported diagnosis of asthma or rhinosinusitis: data from a population-based survey. Chest. 20011. Nov; 120 (5): 1461-7.
56. Buchbauer G. On the biological properties of fragrance compounds and essential oils Wien Med Wochenschr. 2004 Nov; 154 (21-22): 539-47.60. .
57. Blasi F, Tarsia P, Aliberti S, Cosentini R, Allegra L. Chlamydia pneumoniae and Mycoplasma pneumoniae. Semin Respir Crit Care Med. 2005 Dec; 26 (6): 617-24.
58. Bukle J. Aromatherapy for health professionals. Holistic practices help with life transitions. Beginnings. 2005 Winter; 25 (l): 18
59. Buckle J. Clinical aromatherapy. Therapeutic uses for essential oils. Adv Nurse Pract. 2002 May; 10 (5): 67-8, 88. Review PMID: 12420533
60. Baker S. ATS policy on the conservation of plants used in aromatherapy. Coplement Ther Clin Pract. 2005 May; 11 (2): 137-8.
61. Blasi F. The pathogenesis of community-acquired pneumonia. Eur Respir Rev 2004; 13: 91,80-84
62. Belcher I. Aromatherapy growing rapidly. Beginnings. 1996 Feb; 16 (2): 4.
63. Buchbauer G, Jirovetz L, Jager W, Dietrich H, Plank C. Aromatherapy: evidence for sedative effects of the essential oil of lavender after inhalation. Z Naturforsch C. 1991 Nov-Dec; 46 (l 1-12): 1067-72
64. Braga PC, Dal Sasso M, Culici M, Galastri L, Marceca MT, GufFanti EE. Antioxidant potential of thymol determined by chemiluminescence inhibition in human neutrophils and cell-free systems. Pharmacology. 2006; 76 (2): 61-8.Epub 2005 Nov 11.
65. Hasani A, Pavia D, Toms N, Dilworth P, Agnew JE. Effect of aromatics on lung mucociliary clearance in patients with chronic airways obstruction. J Altern Complement Med. 2003 Apr;9(2):243-9.
66. Caramia G, Pastorelli G. Antipneumococca! vaccine: up date and prospective. Minerva Pediatr. 2005 Oct;57(5):229-41.
67. Casado JA, Merino J, Cid J, Subira ML, Sanchez-Ibarrola A Oxidizing agents and free radicals in biomedicine Rev Med Univ Navarra. 1996 Jul-Sep;40(3):31-40.
68. Grabenstein J. ImmunoFacts. Vaccines and Immunologic Drugs. Wolters Kluwer Health, Inc.; 2006
69. DeLeo FR. Modulation of phagocyte apoptosis by bacterial pathogens. Apoptosis. 2004 Jul;9(4):399-413.
70. Ewig S., Schlochtermeier M., Goke N., Niederman M.S. Applying Sputum as a Diagnostic Tool in Pneumonia // Chest. 2002. - Vol. 121. - P. 1486-1492.
71. Eschenbruch N. "A risk for life and health?" Alternative medicine practitioners, pharmacologists and drug regulation in the 1970's Schweiz Rundsch Med Prax. 2006 Apr 19;95(16):652-5.
72. Edwards-Jones V, Greenwood JE; Manchester Burns Research Group. What's new in burn microbiology? James Laing Memorial Prize Essay 2000. Bums. 2003 Feb;29(l): 15-24.и/
73. European Respiratory Society/European Lung Foundation. European Lung White Book. The First Comprehensive Survey on Respiratory Health in Europe. Loddenkemper R, Gibson GJ, Sibille Y, eds. Sheffield, UK, ERSJ, 2003
74. Edwards-Jones V, Greenwood JE; Manchester Burns Research Group. What's new in burn microbiology? James Laing Memorial Prize Essay 2000. Burns. 2003 Feb;29(l):15-24.
75. Ernst E, White A. The BBC survey of complementary medicine use in the UK. Complement Ther Med. 2000 Mar;8(l):32-6.
76. Forman HJ, Torres M Signaling by the respiratory burst in macrophages. IUBMB Life. 2001 Jun;51(6):365-71.
77. Freymann H, Rennie T, Bates I, Nebel S, Heinrich M. Knowledge and Use of Complementary and Alternative Medicine among British Undergraduate Pharmacy Students. Pharm World Sci. 2006 May 11
78. Foster WM. Mucociliary transport and cough in humans. Pulm Pharmacol Ther. 2002;15(3):277-82.
79. Faustova ME. The bactericidal action of some essential oils on the causative agents of acute and chronic inflammatory lung diseases Zh Mikrobiol Epidemiol Immunobiol. 1993 Nov-Dec;(6): 117-8.
80. File TM. Community-acquired pneumonia. Lancet. 2003 Dec 13;362(9400): 1991 -2001.
81. Gotfried M.H. Epidemiology of clinically diagnosed community-acquired pneumonia in the primary care setting: results from the 1999-2000 respiratory surveillance program // Am. J. Med. 2001. - Vol. 11 l(suppl 1). - P. 25-29.jlL
82. Galla JH. IgA nephropathy. Kidney Int 1995; 47: 377-387.
83. Hiemstra P.S. Immunoglobulin A in asthma: friend or foe? Eur Respir J 1998; 12:517-518
84. Hall K, Giles-Corti B. Complementary therapies and the general practitioner. A survey of Perth GPs. Aust Fam Physician. 2000 Jun;29(6):602-6.
85. Happel KI, Nelson S. Alcohol, immunosuppression, and the lung. Proc Am Thorac Soc. 2005;2(5):428-32.
86. Janeway C. Immunobiology: the immune system in health and disease.
87. Jones ML, Mulligan MS, Flory CM, Ward PA, Warren JS. Potential role of monocyte chemoattractant protein 1/JE in monocyte/macrophage-dependent IgA immune complex alveolitis in the rat. J Immunol 1992; 149: 2147-2154.
88. Kiffin R, Bandyopadhyay U, Cuervo AM. Oxidative stress and autophagy. Antioxid Redox Signal. 2006 Jan-Feb;8(l-2):152-62.
89. Kobayashi SD, Voyich JM, Burlak C, DeLeo FR. Neutrophils in the innate immune response. Arch Immunol Ther Exp (Warsz). 2005 Nov-Dec;53(6):505-17
90. Kim R, Emi M, Tanabe K, Murakami S, Uchida Y, Arihiro K. Regulation and interplay of apoptotic and non-apoptotic cell death. J Pathol. 2006 Feb;208(3):319-26.
91. Kupczyk M, Kuna P. Mucolytics in acute and chronic respiratory tract disorders. II.Uses for treatment and antioxidant properties Pol Merkuriusz Lek.2002 Mar;12(69):248-52.г/3
92. Lamm ME, Nedrud JG, Kaetzel CS, Mazanec MB. IgA and mucosal defense. APMIS 1995; 103: 241-246.
93. Morton HC, van Egmond M, van de Winkel JG. Structure and function of human IgA Fc receptors (Fc alpha R). Crit Rev Immunol 1996; 16: 423—440.
94. Mayaud C, Fartoukh M, Prigent H, Lavole A, Gounand V, Parrot A. Acute forms of diffuse interstitial hypoxemic pneumonia in immunocompetent' patients. Rev Pneumol Clin. 2005 Apr;61(2):70-7.
95. Mandell LA. Related Articles, Update on community-acquired pneumonia. New pathogens and new concepts in treatment. Postgrad Med. 2005 Oct;118(4):35-6, 41-6.
96. Moraes TJ, Zurawska JH, Downey GP. Neutrophil granule contents in thepathogenesis of lung injury. Curr Opin Hematol. 2006 Jan;13(l):21-7.t
97. MacMahon S, Kermode S. A clinical trial of the effect of aromatherapy Complement TherNurs Midwifery. 2004 Feb;10(l):58-60. Patol Fiziol Eksp Тег. 1990 Jan-Feb;( 1 ):27-30
98. Norton L. Complementary therapies in practice: the ethical issues. J Clin Nurs. 1995 Nov;4(6):343-8.
99. Neiss A., Elkharrat D., Kohno S., Hospitalisation costs for community-acquired pneumonia (CAP) in France (F), Germany (D), Japan (J) and USA. ERS congress 2004. Poster # 182.
100. Pettigrew AC, King MO, McGee K, Rudolph C. Complementary therapy use by women's health clinic clients. Altern Ther Health Med. 2004 Nov-Dec;10(6):50-5
101. Philipp B. Aroma therapy: there are hardly any limitations in this gentle method Pflege Z. 1999 Qct;52(10):696-9.ft
102. Pirotta MV, Cohen MM, Kotsirilos V, Farish SJ. Complementary therapies: have they become accepted in general practice? Med J Aust. 2000 Feb 7; 172(3): 105-9.
103. Roots R. Estimation of life times and diffusion distances of radicals involved in X-ray-induced DNA strand breaks or killing of mammalian cells // Radiat. Res.-1975.- Vol. 64.-P.306-320
104. Stocks N, Turnidge J, Crockett A. Lower respiratoiy tract infections and community acquired pneumonia in adults. Aust Fam Physician. 2004 May;33(5):297-301.
105. Sawazaki K, Sakuraba H, Masudai F, Ishii C, Yokoyama K. Use of complementaiy and alternative medicines among factory workers: investigation of workers in manufacturing Sangyo Eiseigaku Zasshi. 2005 Nov;47(6):254-8.
106. Segal AW. How neutrophils kill microbes. Annu Rev Immunol. 2005;23:197-223.
107. Schafer Т. Epidemiology of complementary alternative medicine for asthma and allergy in Europe and Germany. Ann Allergy Asthma Immunol. 2004 Aug;93(2 Suppl 1):S5-10.
108. Thomas RE, Jefferson TO, Demicheli V, Rivetti D. Influenza vaccination for health-care workers who work with elderly people in institutions: a systematic review. Lancet Infect Dis. 2006 May;6(5):273-9.
109. Wills PJ, Cole PJ. Mucolytic and mucokinetic therapy. Pulm Pharmacol. 1996 Aug;9(4): 197-204.
110. Wark PA, McDonald V, Jones AP. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev. 2005 Jul 20;(3)
111. Waite S, Jeudy J, White CS. Acute lung infections in normal and immunocompromised hosts. Radiol Clin North Am. 2006 Mar;44(2):295-3156th ed. New York, 2005, 823 p
112. Woodhead M. Community-acquired pneumonia in Europe: causative pathogens and resistance patterns Eur Respir J 2002; 20: Suppl. 36, 20s-27s
113. Zhao RJ, Koo BS, Kim GW, Jang EY, Lee JR, Kim MR, Kim SC, Kwon YK, Kim KJ, Huh TL, Kim DH, Shim I, Yang CH. The essential oil from Angelica gigas NAKAI suppresses nicotine sensitization.Biol Pharm Bull. 2005 Dec;28(12):2323-6.
Обратите внимание, представленные выше научные тексты размещены для ознакомления и получены посредством распознавания оригинальных текстов диссертаций (OCR). В связи с чем, в них могут содержаться ошибки, связанные с несовершенством алгоритмов распознавания.
В PDF файлах диссертаций и авторефератов, которые мы доставляем, подобных ошибок нет.
Научная библиотека диссертаций и авторефератов disserCat http://www.dissercat.com/content/otsenka-effektivnosti-primeneniya-ingalyatsii-efirnykh-masel-v-kompleksnoi-terapii-vnebolnic#ixzz3I2dm00cn
Want to see more scientific studies on essential oils?
www.essentialoilskeptic.com
